Literature DB >> 26443480

Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.

Ji Eun Oh1, Takashi Ohta1,2, Naosuke Nonoguchi1,3, Kaishi Satomi1, David Capper4, Daniela Pierscianek1,5, Ulrich Sure5, Anne Vital6, Werner Paulus7, Michel Mittelbronn8, Manila Antonelli9, Paul Kleihues10, Felice Giangaspero9,11, Hiroko Ohgaki1.   

Abstract

The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma. IDH mutations are the genetic hallmark of secondary glioblastomas. Gliosarcomas and giant cell glioblastomas are rare histological glioblastoma variants, which usually develop rapidly. We determined the genetic patterns of 36 gliosarcomas and 19 giant cell glioblastomas. IDH1 and IDH2 mutations were absent in all 36 gliosarcomas and in 18 of 19 giant cell glioblastomas analyzed, indicating that they are histological variants of primary glioblastoma. Furthermore, LOH 10q (88%) and TERT promoter mutations (83%) were frequent in gliosarcomas. Copy number profiling using the 450k methylome array in 5 gliosarcomas revealed CDKN2A homozygous deletion (3 cases), trisomy chromosome 7 (2 cases), and monosomy chromosome 10 (2 cases). Giant cell glioblastomas had LOH 10q in 50% and LOH 19q in 42% of cases. ATRX loss was detected immunohistochemically in 19% of giant cell glioblastomas, but absent in 17 gliosarcomas. These and previous results suggest that gliosarcomas are a variant of, and genetically similar to, primary glioblastomas, except for a lack of EGFR amplification, while giant cell glioblastoma occupies a hybrid position between primary and secondary glioblastomas.
© 2015 International Society of Neuropathology.

Entities:  

Keywords:  10q; 19q; IDH mutation; TERT mutation; giant cell glioblastoma; gliosarcoma

Mesh:

Year:  2015        PMID: 26443480     DOI: 10.1111/bpa.12328

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  22 in total

1.  Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.

Authors:  Rachael A Vaubel; Alissa A Caron; Seiji Yamada; Paul A Decker; Jeanette E Eckel Passow; Fausto J Rodriguez; Amulya A Nageswara Rao; Daniel Lachance; Ian Parney; Robert Jenkins; Caterina Giannini
Journal:  Brain Pathol       Date:  2017-04-02       Impact factor: 6.508

Review 2.  Giants and monsters: Unexpected characters in the story of cancer recurrence.

Authors:  Shai White-Gilbertson; Christina Voelkel-Johnson
Journal:  Adv Cancer Res       Date:  2020-05-04       Impact factor: 6.242

3.  Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.

Authors:  Chuan-Dong Cheng; Cheng Chen; Li Wang; Yong-Fei Dong; Yang Yang; Yi-Nan Chen; Wan-Xiang Niu; Wen-Chao Wang; Qing-Song Liu; Chao-Shi Niu
Journal:  Anal Cell Pathol (Amst)       Date:  2022-06-15       Impact factor: 4.133

Review 4.  Glioma Subclassifications and Their Clinical Significance.

Authors:  Ricky Chen; Matthew Smith-Cohn; Adam L Cohen; Howard Colman
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 5.  Understanding TERT Promoter Mutations: A Common Path to Immortality.

Authors:  Robert J A Bell; H Tomas Rube; Ana Xavier-Magalhães; Bruno M Costa; Andrew Mancini; Jun S Song; Joseph F Costello
Journal:  Mol Cancer Res       Date:  2016-03-03       Impact factor: 5.852

6.  Radiotherapy plus concomitant temozolomide in primary gliosarcoma.

Authors:  Sebastian Adeberg; Denise Bernhardt; Semi Ben Harrabi; Christian Diehl; Christian Koelsche; Stefan Rieken; Andreas Unterberg; Andreas von Deimling; Juergen Debus
Journal:  J Neurooncol       Date:  2016-03-30       Impact factor: 4.130

7.  Nuclear receptor NR5A2 negatively regulates cell proliferation and tumor growth in nervous system malignancies.

Authors:  Dimitrios Gkikas; Dimitris Stellas; Alexia Polissidis; Theodora Manolakou; Maroula G Kokotou; George Kokotos; Panagiotis K Politis
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-28       Impact factor: 11.205

8.  Gliosarcoma with Primary Skull Base Invasion.

Authors:  Quoc-Bao D Nguyen; Avital Perry; Christopher S Graffeo; Cody L Nesvick; Aditya Raghunathan; Mark E Jentoft; Brian P O'Neill; Padraig P Morris; Jonathan M Morris; Jamie J Van Gompel
Journal:  Case Rep Radiol       Date:  2016-12-08

Review 9.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

10.  Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.

Authors:  Margaret Pain; Huaien Wang; Eunjee Lee; Maya Strahl; Wissam Hamou; Robert Sebra; Jun Zhu; Raymund L Yong
Journal:  Oncotarget       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.